European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected ...

The European Commission approves RHHBY's Columvi combo to treat adult patients with diffuse large B-cell lymphoma after ...

Eisai (ESAIY) and Biogen (BIIB) announced an update on the ongoing regulatory review of the Marketing Authorization Application, MAA, for ...

Following the nod in the EU, BIIB & Eisai's Leqembi becomes the first therapy to slow the progression of early Alzheimer's ...

Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer ...

Eisai and Biogen can finally put their European regulatory uncertainty surrounding Alzheimer's disease medicine Leqembi ...

Eisai & Biogen announce update on regulatory review of MAA for lecanemab to treat early Alzheimer’s disease by European Commission: Tokyo Wednesday, April 16, 2025, 11:00 Hrs [I ...

EU approves expanded use of ABBV's Rinvoq and AZN's Imfinzi and Enhertu. NVS set to invest $23B to boost U.S. manufacturing.

In the US, healthcare costs and prices have been increasing. According to the Centers for Medicare & Medicaid Services, U.S.

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine ...

The Physicians Committee for Responsible Medicine, a nonprofit that advocates for nonanimal science, is applauding the new commissioner of the U.S. Food and Drug Administration, Marty Makary, MD, MPH, ...